Superworth

Schrodinger price to free cash flow SDGR

Market value divided by free cash flow over the last twelve months, since 2021.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
73.4×
May 2026
6-year median
71.0×
6-year range
56.1× to 484×
Peer median
8.1×

Schrodinger's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2026, at 73.4×.

On the days it had one over the last 6 years, its median was 71.0×, from 56.1× in Sep 2025 to 484× in Aug 2021.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far73.4×65.7×75.5×
202563.5×56.1×81.5×
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
2022n/m a value too high to mean anything
2021484×337×484×

Against its peers

Companies in Drug Manufacturers - General nearest Schrodinger's size, closest first, today.

CompanyPrice to free cash flow
SDGRSchrodingern/m
ANIPANI Pharmaceuticals9.6×
PAHCPhibro Animal Health160×
HRMYHarmony Biosciencesn/m
ANABAnaptysbion/m
PCRXPacira BioSciences8.1×
PBHPrestige Consumer Healthcare9.6×
OMEROmerosn/m
NRIXNurix Therapeutics7.5×
AMPHAmphastar Pharmaceuticals7.0×
OGNOrganon6.4×
Peer median8.1×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Schrodinger

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.